|
Organ donor animal | Perfusion system | Ventilation system | Drug/formulation | Formulation application | Analytics | References |
|
Rat | Recirculating flow, 15 mL/min; Krebs-Ringer/Krebs-Henseleit buffer + 4% BSA | Alternating “negative” pressure; tidal volume: ~1 mL, ventilation frequency: 7–28 strokes/min | Fluorescent dyes, labeled dextrans, polypeptides (polyaspartamide, insulin); solution | “Forced solution instillation” | Fluorescence spectroscopy, ELISA | [142–152] |
Recirculating or single-pass flow, 7–11 mL/min; Krebs-Ringer buffer + 4.5% BSA | Alternating “negative” pressure; tidal volume: ~1 mL, ventilation frequency: 70 strokes/min | Budesonide; solution | Instillation | HPLC, liquid scintillation counting | [153] |
Recirculating flow, 5 mL/min; Krebs-Henseleit buffer + 3% BSA | “Positive” pressure inflation; tidal volume: 2, 4 mL, ventilation frequency: 60, 30 strokes/min | Levofloxacin; solution | Nebulization | HPLC | [154] |
Single-pass flow, ~17 mL/min; Krebs-Ringer buffer + 2% BSA | Alternating “negative” pressure; tidal volume: ~1 mL, ventilation frequency: 75 strokes/min | Budesonide, formoterol, terbutaline; powder | Powder aerosolization (DustGun® technology) | LC-MS/MS | [155] |
Recirculating flow, 10–12 mL/min; Krebs-Ringer buffer + 4.5% BSA | Alternating “negative” pressure; tidal volume: ~1 mL, ventilation frequency: 80 strokes/min | Diverse low molecular weight therapeutic agents, labelled dextrans, oligopeptides; solution | Nebulization, instillation (Aeroprobe® technology) | Fluorescence spectroscopy, LC-MS/MS | [156, 157] |
|
Guinea pig | Single-pass flow, 10 mL/min; Krebs-Ringer buffer + 4.5% BSA | Alternating “negative” pressure; tidal volume: ~2 mL, ventilation frequency: 80 strokes/min | Xanthines; solution | Instillation | liquid scintillation counting | [158] |
|
Rabbit | Recirculating flow, 100 mL/min; Krebs-Henseleit buffer (+ 4% hydroxyethyl-amylopectine) | “Positive” pressure inflation; tidal volume: 30 mL, ventilation frequency: 30 strokes/min | Fluorescent dyes, salbutamol, iloprost; solution, nanosuspension | Nebulization, instillation | Fluorescence spectroscopy; HPLC; RIA | [106, 159–161] |
Recirculating flow; Krebs-Ringer buffer + 4.5% BSA | Alternating “negative” pressure | Isoproterenol, isoproterenol prodrugs; solution | Nebulization, instillation | HPLC | [162, 163] |
|